Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer

References

• Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001;357:539–545.
   PubMed Web of Science ®Google Scholar
• Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009;30:1073–1081.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860–867.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883–899.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436–444.
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71–78.
   PubMed Web of Science ®Google Scholar
• Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004;4:641–648.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
   PubMed Web of Science ®Google Scholar
• Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004;279:48487–48490.
   PubMed Web of Science ®Google Scholar
• Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: A critical review. J Intern Med 2008;264:295–314.
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–454.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: New insights from an old molecule. Qjm 2003;96:793–807.
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003;111:1805–1812.
   PubMed Web of Science ®Google Scholar
• Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007;61:824–833.
   PubMed Web of Science ®Google Scholar
• Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217–2224.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010;28:2719–2726.
   PubMed Web of Science ®Google Scholar
• Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291:585–590.
   PubMed Web of Science ®Google Scholar
• Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006;66:2483–2487.
   PubMed Web of Science ®Google Scholar
• Heikkilä K, Silander K, Salomaa V, Jousilahti P, Koskinen S, Pukkala E et al. C-reactive protein-associated genetic variants and cancer risk: Findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies. Eur J Cancer 2011;47:404–412.
   Google Scholar
• Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413–2418.
   PubMed Web of Science ®Google Scholar
• Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S; Japan Public Health Center-Based Prospective Study Group. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 2006;15:690–695.
   Web of Science ®Google Scholar
• Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: The Rotterdam Study. J Clin Oncol 2006;24:5216–5222.
   PubMed Web of Science ®Google Scholar
• Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: A prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006;15:381–384.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG. Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. Curr Opin Lipidol 2009;20:393–401.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF et al.; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010;31:2844–2853.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Tybjærg-Hansen A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: Concordance and discordance with cardiovascular disease risk. Curr Opin Lipidol 2011;22:113–122.
   PubMed Web of Science ®Google Scholar
• Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149–163.
   PubMed Web of Science ®Google Scholar
• Burtis CA, Ashwood ER, and Bruns DE, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4. 2006. Informa Healthcare.
   Google Scholar
• Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930;52:561–571.
   PubMedGoogle Scholar
• Osmand AP, Friedenson B, Gewurz H, Painter RH, Hofmann T, Shelton E. Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci USA 1977;74:739–743.
   PubMed Web of Science ®Google Scholar
• Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999;7:169–177.
   PubMed Web of Science ®Google Scholar
• Kinoshita CM, Ying SC, Hugli TE, Siegel JN, Potempa LA, Jiang H et al. Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. Biochemistry 1989;28:9840–9848.
   PubMed Web of Science ®Google Scholar
• Ji SR, Wu Y, Zhu L, Potempa LA, Sheng FL, Lu W et al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J 2007;21:284–294.
   PubMedGoogle Scholar
• Whitehead AS, Bruns GA, Markham AF, Colten HR, Woods DE. Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1. Science 1983;221:69–71.
   PubMed Web of Science ®Google Scholar
• Lei KJ, Liu T, Zon G, Soravia E, Liu TY, Goldman ND. Genomic DNA sequence for human C-reactive protein. J Biol Chem 1985;260:13377–13383.
   Google Scholar
• MacGregor AJ, Gallimore JR, Spector TD, Pepys MB. Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: A comparison of monozygotic and dizygotic twins. Clin Chem 2004;50:130–134.
   PubMed Web of Science ®Google Scholar
• Volanakis JE. Human C-reactive protein: Expression, structure, and function. Mol Immunol 2001;38:189–197.
   PubMed Web of Science ®Google Scholar
• Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A et al. Human CRP gene polymorphism influences CRP levels: Implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003;23:2063–2069.
   PubMed Web of Science ®Google Scholar
• Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005;77:64–77.
   PubMed Web of Science ®Google Scholar
• Kovacs A, Green F, Hansson LO, Lundman P, Samnegård A, Boquist S et al. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 2005;178:193–198.
   PubMed Web of Science ®Google Scholar
• Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, Lazarus R et al. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet 2005;69:623–638.
   PubMed Web of Science ®Google Scholar
• Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004;13:137–147.
   PubMed Web of Science ®Google Scholar
• Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002;3:14–19.
   PubMed Web of Science ®Google Scholar
• Szalai AJ, Wu J, Lange EM, McCrory MA, Langefeld CD, Williams A et al. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med 2005;83:440–447.
   PubMed Web of Science ®Google Scholar
• Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002;162:217–219.
   PubMed Web of Science ®Google Scholar
• Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. Jama 2009;302:37–48.
   PubMed Web of Science ®Google Scholar
• Reiner AP, Barber MJ, Guan Y, Ridker PM, Lange LA, Chasman DI et al. Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 α are associated with C-reactive protein. Am J Hum Genet 2008;82:1193–1201.
   Google Scholar
• Ridker PM, Pare G, Parker A, Zee RY, Danik JS, Buring JE et al. Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: The Women’s Genome Health Study. Am J Hum Genet 2008;82:1185–1192.
   PubMed Web of Science ®Google Scholar
• Li SP, Goldman ND. Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry 1996;35:9060–9068.
   PubMed Web of Science ®Google Scholar
• Toniatti C, Demartis A, Monaci P, Nicosia A, Ciliberto G. Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. Embo J 1990;9:4467–4475.
   PubMedGoogle Scholar
• Timpson NJ, Nordestgaard BG, Harbord RM, Zacho J, Frayling TM, Tybjærg-Hansen A et al. C-reactive protein levels and body mass index: Elucidating direction of causation through reciprocal Mendelian randomization. Int J Obes (Lond) 2011;35:300–308.
   Web of Science ®Google Scholar
• Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon β 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84:7251–7255.
   PubMed Web of Science ®Google Scholar
• Hutchinson WL, Noble GE, Hawkins PN, Pepys MB. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest 1994;94:1390–1396.
   Google Scholar
• Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;91:1351–1357.
   PubMed Web of Science ®Google Scholar
• Pepys MB, Dash AC, Fletcher TC, Richardson N, Munn EA, Feinstein A. Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. Nature 1978;273:168–170.
   Google Scholar
• Pepys MB. Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology 1979;37:637–641.
   Google Scholar
• Volanakis JE, Wirtz KW. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature 1979;281:155–157.
   PubMed Web of Science ®Google Scholar
• Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974;112:2135–2147.
   PubMed Web of Science ®Google Scholar
• Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Part 2. Clin Chem 2001;47:418–425.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M et al.; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511.
   PubMed Web of Science ®Google Scholar
• Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001;47:426–430.
   PubMed Web of Science ®Google Scholar
• Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: Implications for cardiovascular disease risk assessment. Clin Chem 2003;49:1258–1271.
   PubMed Web of Science ®Google Scholar
• Young I, Rifai N. High-sensitivity C-reactive protein and cardiovascular disease. Clin Chem 2009;55:201–202.
   Google Scholar
• Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: Age-related values in the adult general population. Clin Chem 2000;46:934–938.
   PubMed Web of Science ®Google Scholar
• Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005;352:1611–1613.
   PubMed Web of Science ®Google Scholar
• Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE et al. C-reactive protein and risk of breast cancer. J Natl Cancer Inst 2007;99:890–894.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713–716.
   PubMed Web of Science ®Google Scholar
• Imhof A, Fröhlich M, Loewel H, Helbecque N, Woodward M, Amouyel P et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 2003;49:669–672.
   PubMed Web of Science ®Google Scholar
• Rifai N, Ridker PM. Population distributions of C-reactive protein in apparently healthy men and women in the United States: Implication for clinical interpretation. Clin Chem 2003;49:666–669.
   PubMed Web of Science ®Google Scholar
• Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women’s Health Study). Am J Cardiol 2004;93:1238–1242.
   PubMed Web of Science ®Google Scholar
• Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444–450.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230–235.
   PubMed Web of Science ®Google Scholar
• Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237–242.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Adourian AS, Freiberg JJ, Guo Y, Muntendam P, Falk E. Risk factors for near-term myocardial infarction in apparently healthy men and women. Clin Chem 2010;56:559–567.
   Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–1565.
   PubMed Web of Science ®Google Scholar
• Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897–1908.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425–428.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. Jama 2001;285:2481–2485.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207.
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851–1861.
   PubMed Web of Science ®Google Scholar
• Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847–850.
   PubMed Web of Science ®Google Scholar
• Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997;82:4196–4200.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 2003;23:650–655.
   Google Scholar
• Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972–978.
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD et al.; West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596–1600.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama 2001;286:327–334.
   PubMed Web of Science ®Google Scholar
• Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol 2010;56:789–795.
   PubMed Web of Science ®Google Scholar
• Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 2010;30:1672–1678.
   PubMed Web of Science ®Google Scholar
• Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. Jama 2003;290:2945–2951.
   PubMed Web of Science ®Google Scholar
• Dahl M, Vestbo J, Zacho J, Lange P, Tybjærg-Hansen A, Nordestgaard BG. C reactive protein and chronic obstructive pulmonary disease: A Mendelian randomisation approach. Thorax 2011;66:197–204.
   PubMed Web of Science ®Google Scholar
• Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and all-cause mortality–the Copenhagen City Heart Study. Eur Heart J 2010;31:1624–1632.
   PubMed Web of Science ®Google Scholar
• Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 2005;142:425–432.
   PubMed Web of Science ®Google Scholar
• Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: A systematic review of prospective studies. Int J Cancer 2008;123:1133–1140.
   PubMed Web of Science ®Google Scholar
• Platz EA, De Marzo AM, Erlinger TP, Rifai N, Visvanathan K, Hoffman SC et al. No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate 2004;59:393–400.
   Google Scholar
• Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010;138:2101–2114.e5.
   Google Scholar
• Cole SW. Chronic inflammation and breast cancer recurrence. J Clin Oncol 2009;27:3418–3419.
   PubMed Web of Science ®Google Scholar
• De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256–269.
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S. Immune surveillance: A balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008;18:11–18.
   PubMed Web of Science ®Google Scholar
• Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer 2010;10:2–3.
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Ebrahim S. ‘Mendelian randomization’: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1–22.
   PubMed Web of Science ®Google Scholar
• Smith GD, Ebrahim S. Mendelian randomization: Prospects, potentials, and limitations. Int J Epidemiol 2004;33:30–42.
   PubMed Web of Science ®Google Scholar
• Nitsch D, Molokhia M, Smeeth L, DeStavola BL, Whittaker JC, Leon DA. Limits to causal inference based on Mendelian randomization: A comparison with randomized controlled trials. Am J Epidemiol 2006;163:397–403.
   PubMed Web of Science ®Google Scholar
• Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE. C-reactive protein and the risk of cancer: A mendelian randomization study. J Natl Cancer Inst 2010;102:202–206.
   PubMedGoogle Scholar
• Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001;358:1356–1360.
   PubMed Web of Science ®Google Scholar
• Smith GD. Mendelian randomization for strengthening causal inference in observational studies: Application to gene x environment interactions. Perspect Psycholl Sci 2010;5:527–545.
   Google Scholar
• Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 2011;
   Google Scholar
• Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies of common genetic variants and cancer: Quantification of bias. J Natl Cancer Inst 2000;92:1151–1158.
   PubMedGoogle Scholar
• Schmid M, Schneitter A, Hinterberger S, Seeber J, Reinthaller A, Hefler L. Association of elevated C-reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer. Obstet Gynecol 2007;110:1231–1236.
   Google Scholar
• Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A et al. C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol 2007;107:114–117.
   PubMed Web of Science ®Google Scholar
• Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y, Tanaka K et al. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 2008;98:540–544.
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, Christensen IJ, Sørensen S, Moesgaard F, Brünner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000;7:617–623.
   PubMed Web of Science ®Google Scholar
• Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R et al. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 2005;92:21–23.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005;103:1856–1864.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T. Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 2003;238:197–202.
   Google Scholar
• Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: The TNM-C score. J Urol 2009;181:1004–12; discussion 1012.
   Google Scholar
• Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 2008;101:978–981.
   Google Scholar
• Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG et al.; ASCENT Investigators. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: Results from the ASCENT trial. Cancer 2008;112:2377–2383.
   PubMed Web of Science ®Google Scholar
• Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: A cohort study. Breast Cancer Res 2011;13:R55.
   PubMed Web of Science ®Google Scholar
• Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009;27:3437–3444.
   PubMed Web of Science ®Google Scholar
• Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008;14:710–714.
   PubMed Web of Science ®Google Scholar
• O’Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R. Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol 2010;5:988–992.
   Google Scholar
• Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: Results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin Chem 2008;54:335–342.
   PubMed Web of Science ®Google Scholar
• Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 2009;249:788–793.
   PubMed Web of Science ®Google Scholar
• Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845–856.
   PubMed Web of Science ®Google Scholar
• Sawyers CL. The cancer biomarker problem. Nature 2008;452:548–552.
   PubMed Web of Science ®Google Scholar
• Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers–blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 2011;8:142–150.
   PubMed Web of Science ®Google Scholar